Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Canadian Small Cap Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Pete Hall who wrote (175)	7/13/1998 3:17:00 PM
From: sceptre	Respond to of 512

HZN/ASE Followers, Pete hit the nail on the head. The underlying strength of HZN is the generic drug lines, along with with the inexpensive ulcer/bacterial test kits. These "pylori test kits" provide an accurate, quick, and less complicated means of testing for ulcers. Contrary to popular belief, ulcers are caused by BACTERIA, and can be treated effectively 9 times out of 10 with an anti-biotic. Also the generic drug line is another "arm" of HZN. This company is not just another hit and miss drug R&D play. If Anticort were to never be approved, HZN would still be way under valued at it's current price (after the major is approved). If Anticort pans out,(and so far so good), this stock will be absolutely incredible. For those interested, HZN has a thread going in the Bio-stiocks, where I noticed Pete has an informative and up-to-date write-up. Sceptre